Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
COSTS AND EXPENSES:        
Research and development $ 22,201 $ 13,082 $ 57,202 $ 46,542
General and administrative 7,390 5,453 22,161 16,291
  29,591 18,535 79,363 62,833
Operating loss (29,591) (18,535) (79,363) (62,833)
Interest income, net 610 7 825 99
Net loss (28,981) (18,528) (78,538) (62,734)
Preferred stock deemed dividend 4,255
Net loss available to common stockholders $ (28,981) $ (18,528) $ (82,793) $ (62,734)
Net loss per common share, diluted $ (0.69) $ (1.60) $ (3.06) $ (6.02)
Net loss per common share, basic $ (0.69) $ (1.60) $ (3.06) $ (6.02)
Weighted average common shares outstanding, diluted 41,944,289 11,581,367 27,066,489 10,429,028
Weighted average common shares outstanding, basic 41,944,289 11,581,367 27,066,489 10,429,028